# Chronomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/chronomics

- Industry: Biotechnology
- Headquarters: Norwich, UK
- Website: www.chronomics.co.uk
- Total disclosed funding: $1.4M
- Latest round: Seed (Jan 8, 2019)
- Investors on record: 3

## About

Chronomics, Ltd. is a healthcare company that specializes in providing advanced diagnostic solutions for improved patient care and healthcare delivery through innovative biomarker research and laboratory services.Chronomics, Ltd. was founded in 2017 and is headquartered in Norwich, UK. The company focuses on diagnostic solutions that enhance healthcare delivery. Founders include Charles Ball, Daniel Herranz, Rob Thompson, and Toby Call, with Tom Stubbs as the CEO. The company has executed 3 deals, with the most recent round of funding occurring on January 8, 2019, where it raised GBP 1.12 million in a Seed round led by SOSV, joined by Anthemis Group. The company's total amount raised to date stands at GBP 1.12 million.Chronomics, Ltd. provides a comprehensive range of diagnostic solutions, including biomarker research and development, sample collection kits, lab testing, and logistics services. These offerings are aimed at streamlining healthcare operations and improving patient outcomes, serving various sectors such as healthcare providers, telehealth companies, clinical research organizations, and employee benefits consultants across multiple geographical markets, including the United Kingdom and beyond.Chronomics, Ltd. generates revenue primarily through a subscription-based model and partnerships with healthcare organizations. The company offers an all-in-one diagnostics ordering system that allows healthcare facilities to manage their diagnostic processes efficiently, directly generating revenue from customized solutions tailored to client needs. The specific pricing details for individual services are not disclosed, but the offerings are designed to create operational efficiencies and enhance patient care.Chronomics, Ltd. aims to leverage its recent Seed funding of GBP 1.12 million to support the development of new diagnostic products and enhancements to existing services. There are plans to expand into additional markets, focusing on areas where healthcare innovation is a priority globally. The funding will facilitate research and development activities, enabling the introduction of new solutions designed to meet current healthcare challenges.

## Funding rounds

- Seed, Jan 8, 2019, $1.4M — Anthemis, SOSV
- Seed, Sep 14, 2018 — SOSV
- Seed, Dec 22, 2017 — SOSV, RebelBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- RebelBio — Seed
- Anthemis (https://capitalatlas.ai/funds/anthemis) — Seed